INOPP Forum
Pharmacovigilance Requirements in Zimbabwe
Quote from VigiServe Admin on November 28, 2020, 5:49 AMThe pharmacovigilance (PV) system in Zimbabwe is well-established for a middle-income African country, fully aligned with WHO standards and contributing to VigiBase via VigiFlow. The Medicines Control Authority of Zimbabwe (MCAZ) serves as the primary regulatory body and houses the National Pharmacovigilance Centre (part of the Pharmacovigilance and Clinical Trials Division – PVCT). MCAZ oversees both post-marketing PV and clinical trials under the Medicines and Allied Substances Control Act [15:03] and related regulations.
Key guiding documents (updated as of 2024–2025):
- MCAZ PVCT GL02 Rev 2 May 2024 — Pharmacovigilance Guideline for Pharmaceutical Industry (main reference for MAHs).
- Zimbabwe National Pharmacovigilance Policy Handbook (latest edition ~2021–2025).
- Electronic PV reporting manuals (e.g., External e-PV User Manual Rev 1 October 2024).
- Specific guidelines for vaccines (e.g., COVID-19 AEFI surveillance) and clinical trials.
MCAZ supports multiple reporting channels: paper forms, mobile/desktop/web apps (Android, iOS, Windows, Mac, Linux, browser-based), and E2B format for industry/clinical trial reports.
Legal Framework and Governance MCAZ regulates medicines, medical devices, and clinical trials, focusing on detection, assessment, understanding, and prevention of adverse effects. The National Pharmacovigilance Centre collects/manages reports, detects signals, assesses risks, issues alerts, and coordinates with WHO. An expert committee reviews reports for regulatory actions. Active surveillance applies to high-risk products; annual HCP training and public awareness campaigns are conducted.
Organization and Personnel Marketing Authorization Holders (MAHs)/pharmaceutical industry must establish and maintain a PV system per MCAZ guidelines.
- Appoint a responsible person (often termed Qualified Person for Pharmacovigilance or equivalent) approved by MCAZ for monitoring safety.
- No formal PV System Master File (PSMF) requirement is explicitly mandated in public summaries, though PV procedures must be documented and available.
Individual Case Safety Reports (ICSRs) – Post-Marketing Healthcare professionals, patients/consumers, and MAHs report suspected ADRs, medication errors, quality issues, or vaccine events (AEFIs).
- Channels: Spontaneous ADR forms (PVF 01), consumer forms (PVF 109), e-reporting apps, or E2B.
- Timelines: Not rigidly fixed in all public documents (e.g., no universal 15/90-day calendar rule stated), but serious/unexpected ADRs must be reported promptly (aligned with WHO/ICH expectations; industry guideline emphasizes expedited for serious cases, often within days/weeks in practice).
- All reports feed into national analysis and VigiBase.
Periodic Benefit-Risk Evaluation Reports (PBRER/PSUR) MAHs submit periodic safety updates as required by MCAZ guidelines (typically aligned with ICH E2C-like formats). Frequency is not rigidly standardized publicly (e.g., no mandatory 6-monthly/annual cycle for all); submissions occur during renewals, variations, or safety concerns.
Risk Management Plans (RMP) Not mandatory for all products; implemented reactively for high-risk cases or based on signal detection.
Signal Management and Emerging Safety Issues MCAZ/National Centre performs ongoing surveillance and signal detection. MAHs monitor data and notify significant/emerging issues promptly (no fixed 5–45 day timelines publicly detailed beyond general promptness).
Clinical Trials-Related Safety Requirements Clinical trials are regulated by MCAZ's Clinical Trial Unit (PVCT Division) per Guidelines for Clinical Trial Application and Authorization (MCAZ-PVCT-GL04 Rev 2 August 2024) and Guidelines for Good Clinical Practice in Zimbabwe. Trials require MCAZ authorization (with MOHCC Secretary approval).
- Sponsors/investigators must monitor safety and report serious adverse events/SAEs.
- Suspected Unexpected Serious Adverse Reactions (SUSARs)/SAEs reported expeditiously via joint MCAZ/MRCZ SAE form or electronic system (E2B supported).
- Timelines: Expedited for serious unexpected events (typically 7–15 days per international norms/ICH E2A, with faster for fatal/life-threatening; exact days referenced in trial-specific approvals or GCP guidelines).
- Periodic reporting: Development Safety Update Reports (DSURs) or annual progress/safety reports required/submitted via Clinical Trials Registry or directly to MCAZ.
- Final trial reports (including safety/adverse events summary) due within 90 days post-completion (preliminary ethical evaluation within 30 days).
- Sponsor responsibility for monitoring, causality assessment, DSMB reports (if applicable), and communication to MCAZ/ethics committees.
Additional Monitoring / Other Aspects
- No black triangle scheme.
- Emphasis on active surveillance for priority products (e.g., vaccines, antiretrovirals).
- Inspections (GCP/PV) by MCAZ; reporting volumes improving with e-tools and training, though under-reporting persists in some areas.
Zimbabwe's PV framework is mature within SADC/WHO contexts — more structured than many regional peers (e.g., mandatory industry PV systems, e-reporting platforms, dedicated guidelines) but less prescriptive than full ICH systems (no routine PSUR cycles or PSMF mandates detailed publicly). It balances spontaneous/active reporting with industry obligations.
For precise, product- or trial-specific details (e.g., exact timelines in the latest MCAZ PVCT GL02 Rev 2 or clinical trial forms), consult MCAZ directly via mcaz.co.zw (Pharmacovigilance & Clinical Trials section, downloads portal, or contact PVCT Division), as guidelines are regularly updated (e.g., 2024 revisions). Companies typically align with MCAZ guidelines and WHO/ICH principles for compliance in Zimbabwe.
https://youtu.be/cbAOr-ynDyQ
The pharmacovigilance (PV) system in Zimbabwe is well-established for a middle-income African country, fully aligned with WHO standards and contributing to VigiBase via VigiFlow. The Medicines Control Authority of Zimbabwe (MCAZ) serves as the primary regulatory body and houses the National Pharmacovigilance Centre (part of the Pharmacovigilance and Clinical Trials Division – PVCT). MCAZ oversees both post-marketing PV and clinical trials under the Medicines and Allied Substances Control Act [15:03] and related regulations.
Key guiding documents (updated as of 2024–2025):
- MCAZ PVCT GL02 Rev 2 May 2024 — Pharmacovigilance Guideline for Pharmaceutical Industry (main reference for MAHs).
- Zimbabwe National Pharmacovigilance Policy Handbook (latest edition ~2021–2025).
- Electronic PV reporting manuals (e.g., External e-PV User Manual Rev 1 October 2024).
- Specific guidelines for vaccines (e.g., COVID-19 AEFI surveillance) and clinical trials.
MCAZ supports multiple reporting channels: paper forms, mobile/desktop/web apps (Android, iOS, Windows, Mac, Linux, browser-based), and E2B format for industry/clinical trial reports.
Legal Framework and Governance MCAZ regulates medicines, medical devices, and clinical trials, focusing on detection, assessment, understanding, and prevention of adverse effects. The National Pharmacovigilance Centre collects/manages reports, detects signals, assesses risks, issues alerts, and coordinates with WHO. An expert committee reviews reports for regulatory actions. Active surveillance applies to high-risk products; annual HCP training and public awareness campaigns are conducted.
Organization and Personnel Marketing Authorization Holders (MAHs)/pharmaceutical industry must establish and maintain a PV system per MCAZ guidelines.
- Appoint a responsible person (often termed Qualified Person for Pharmacovigilance or equivalent) approved by MCAZ for monitoring safety.
- No formal PV System Master File (PSMF) requirement is explicitly mandated in public summaries, though PV procedures must be documented and available.
Individual Case Safety Reports (ICSRs) – Post-Marketing Healthcare professionals, patients/consumers, and MAHs report suspected ADRs, medication errors, quality issues, or vaccine events (AEFIs).
- Channels: Spontaneous ADR forms (PVF 01), consumer forms (PVF 109), e-reporting apps, or E2B.
- Timelines: Not rigidly fixed in all public documents (e.g., no universal 15/90-day calendar rule stated), but serious/unexpected ADRs must be reported promptly (aligned with WHO/ICH expectations; industry guideline emphasizes expedited for serious cases, often within days/weeks in practice).
- All reports feed into national analysis and VigiBase.
Periodic Benefit-Risk Evaluation Reports (PBRER/PSUR) MAHs submit periodic safety updates as required by MCAZ guidelines (typically aligned with ICH E2C-like formats). Frequency is not rigidly standardized publicly (e.g., no mandatory 6-monthly/annual cycle for all); submissions occur during renewals, variations, or safety concerns.
Risk Management Plans (RMP) Not mandatory for all products; implemented reactively for high-risk cases or based on signal detection.
Signal Management and Emerging Safety Issues MCAZ/National Centre performs ongoing surveillance and signal detection. MAHs monitor data and notify significant/emerging issues promptly (no fixed 5–45 day timelines publicly detailed beyond general promptness).
Clinical Trials-Related Safety Requirements Clinical trials are regulated by MCAZ's Clinical Trial Unit (PVCT Division) per Guidelines for Clinical Trial Application and Authorization (MCAZ-PVCT-GL04 Rev 2 August 2024) and Guidelines for Good Clinical Practice in Zimbabwe. Trials require MCAZ authorization (with MOHCC Secretary approval).
- Sponsors/investigators must monitor safety and report serious adverse events/SAEs.
- Suspected Unexpected Serious Adverse Reactions (SUSARs)/SAEs reported expeditiously via joint MCAZ/MRCZ SAE form or electronic system (E2B supported).
- Timelines: Expedited for serious unexpected events (typically 7–15 days per international norms/ICH E2A, with faster for fatal/life-threatening; exact days referenced in trial-specific approvals or GCP guidelines).
- Periodic reporting: Development Safety Update Reports (DSURs) or annual progress/safety reports required/submitted via Clinical Trials Registry or directly to MCAZ.
- Final trial reports (including safety/adverse events summary) due within 90 days post-completion (preliminary ethical evaluation within 30 days).
- Sponsor responsibility for monitoring, causality assessment, DSMB reports (if applicable), and communication to MCAZ/ethics committees.
Additional Monitoring / Other Aspects
- No black triangle scheme.
- Emphasis on active surveillance for priority products (e.g., vaccines, antiretrovirals).
- Inspections (GCP/PV) by MCAZ; reporting volumes improving with e-tools and training, though under-reporting persists in some areas.
Zimbabwe's PV framework is mature within SADC/WHO contexts — more structured than many regional peers (e.g., mandatory industry PV systems, e-reporting platforms, dedicated guidelines) but less prescriptive than full ICH systems (no routine PSUR cycles or PSMF mandates detailed publicly). It balances spontaneous/active reporting with industry obligations.
For precise, product- or trial-specific details (e.g., exact timelines in the latest MCAZ PVCT GL02 Rev 2 or clinical trial forms), consult MCAZ directly via mcaz.co.zw (Pharmacovigilance & Clinical Trials section, downloads portal, or contact PVCT Division), as guidelines are regularly updated (e.g., 2024 revisions). Companies typically align with MCAZ guidelines and WHO/ICH principles for compliance in Zimbabwe.
- You need to login to have access to uploads.